The stock of Concordia International Corp (NASDAQ:CXRX) is a huge mover today! About 644,498 shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 88.48% since March 15, 2016 and is downtrending. It has underperformed by 93.96% the S&P500.
The move comes after 8 months positive chart setup for the $181.11 million company. It was reported on Oct, 18 by Barchart.com. We have $9.64 PT which if reached, will make NASDAQ:CXRX worth $297.02M more.
Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 earnings per share, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $66.99 million for 0.68 P/E if the $1.35 EPS becomes a reality. After $1.21 actual earnings per share reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.
Concordia International Corp (NASDAQ:CXRX) Ratings Coverage
Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Laurentian on Tuesday, March 29. The stock has “Hold” rating given by GMP Securities on Monday, August 15. The stock of Concordia International Corp (NASDAQ:CXRX) earned “Buy” rating by S&P Research on Friday, October 16. Scotia Capital maintained the stock with “Sector Outperform” rating in Tuesday, September 29 report. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, October 1. On Monday, October 19 the stock rating was upgraded by Mackie to “Speculative Buy”. The firm has “Underperformer” rating given on Monday, August 15 by IBC. On Friday, October 16 the stock rating was maintained by Scotia Capital with “Sector Outperform”. The stock of Concordia International Corp (NASDAQ:CXRX) has “Buy” rating given on Tuesday, August 11 by Canaccord Genuity. The firm has “Sector Perform” rating by IBC given on Monday, November 30.
According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”
More important recent Concordia International Corp (NASDAQ:CXRX) news were published by: Business.Financialpost.com which released: “Concordia International Corp. faces much more downside â€“ CIBC” on October 14, 2016, also Prnewswire.com published article titled: “Shareholder Class Action Filed Against Concordia International Corp. – CXRX”, Business.Financialpost.com published: “Concordia International Corp takeover unlikely â€“ Goldman” on September 27, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) was released by: Globenewswire.com and their article: “DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Concordia …” with publication date: September 29, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.